Adamas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa induced dyskinesia (LID), and as a treatment for chronic behavioral symptoms associated with traumatic brain injury (TBI). Its portfolio includes product candidates, MDX-8704, being co-developed with Forest Laboratories, Inc. (Forest), for the treatment of moderate to severe dementia associated with Alzheimer's disease, and Namenda XR, which Forest developed and is marketing in the United States under a license from the Company. The Company has completed Phase II/III clinical trial of ADS-5102. ADS-5102 is designed to address many of the limitations of immediate-release amantadine.